ALPCO/Calprotectin CLIA Assay: Expected Values of Calprotectin in Healthy Subjects
American Laboratory Products Company
120 participants
Jul 7, 2025
OBSERVATIONAL
Conditions
Summary
This study is evaluating the levels of calprotectin, a protein found in stool, in healthy adults. Calprotectin is a marker of inflammation in the intestines and can help doctors tell the difference between inflammatory bowel diseases (IBD), like Crohn's disease or ulcerative colitis, and non-inflammatory conditions like irritable bowel syndrome (IBS). In this study, healthy volunteers aged 22 and older will collect a stool sample at home using a simple kit and mail it to the study site. The samples will be tested using a new laboratory method called the ALPCO Calprotectin CLIA assay. The goal is to confirm what level of calprotectin is considered "normal" in people without intestinal disease. Participation involves just one stool sample, and there are no medical procedures. Volunteers will be compensated for their time. The study will help improve how doctors interpret calprotectin test results in clinical settings.
Eligibility
Inclusion Criteria5
- Adults aged ≥22 years
- No abdominal symptoms and no history of inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), or other chronic intestinal disorders
- May have undergone colonoscopy with negative findings within the past month or never undergone colonoscopy
- Able and willing to provide a stool sample according to the collection protocol
- Able to understand the study and sign the informed consent form (ICF)
Exclusion Criteria8
- Unable or unwilling to provide a stool sample
- Known active intestinal cancer or history of intestinal cancer with abnormal clinical findings
- Currently receiving chemotherapy or systemic immunosuppressive medications
- Use of proton pump inhibitors (PPIs) or H2-receptor antagonists within the last 2 weeks
- Use of NSAIDs (including aspirin) for 7 or more days in the past 2 weeks
- Presence of gastrointestinal symptoms such as abdominal pain, diarrhea, altered appetite, weight loss, or anemia
- Samples collected not following protocol requirements
- Any other condition that, in the opinion of the investigator, may interfere with study participation or data validity
Interventions
Measurement of calprotectin in feces
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07089420